Maven Securities LTD acquired a new stake in shares of Surmodics, Inc. (NASDAQ:SRDX - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm acquired 12,000 shares of the company's stock, valued at approximately $366,000. Maven Securities LTD owned 0.08% of Surmodics at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of the company. Hudson Bay Capital Management LP purchased a new stake in Surmodics in the 4th quarter worth $11,880,000. Bardin Hill Management Partners LP purchased a new stake in shares of Surmodics during the fourth quarter worth about $7,440,000. Eisler Capital Management Ltd. bought a new stake in Surmodics during the 4th quarter valued at approximately $5,394,000. Balyasny Asset Management L.P. bought a new stake in Surmodics during the 4th quarter valued at approximately $4,921,000. Finally, Squarepoint Ops LLC lifted its holdings in Surmodics by 154.9% in the 4th quarter. Squarepoint Ops LLC now owns 162,066 shares of the company's stock worth $6,418,000 after purchasing an additional 98,489 shares in the last quarter. Institutional investors own 96.63% of the company's stock.
Surmodics Stock Up 1.2%
NASDAQ SRDX opened at $37.34 on Wednesday. The stock has a 50 day moving average price of $32.40 and a 200-day moving average price of $30.89. Surmodics, Inc. has a one year low of $26.00 and a one year high of $40.38. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.10 and a current ratio of 3.91. The company has a market capitalization of $533.89 million, a P/E ratio of -30.36 and a beta of 1.31.
Surmodics (NASDAQ:SRDX - Get Free Report) last announced its quarterly earnings results on Friday, August 8th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.27. The company had revenue of $29.57 million for the quarter, compared to analysts' expectations of $28.04 million. Surmodics had a negative net margin of 14.59% and a negative return on equity of 2.99%. Surmodics has set its FY 2025 guidance at -0.350--0.200 EPS. As a group, equities analysts predict that Surmodics, Inc. will post 0.2 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on SRDX shares. Barrington Research reaffirmed a "market perform" rating on shares of Surmodics in a report on Monday, August 11th. Zacks Research upgraded shares of Surmodics to a "hold" rating in a research report on Tuesday, August 12th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Surmodics in a research note on Wednesday, April 30th. One analyst has rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $43.00.
Get Our Latest Research Report on SRDX
Surmodics Profile
(
Free Report)
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
See Also
Want to see what other hedge funds are holding SRDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Surmodics, Inc. (NASDAQ:SRDX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Surmodics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surmodics wasn't on the list.
While Surmodics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access